Competing interests
INTERSTITIAL NEPHRITIS, EDWARDS
Competing interests: All authors have completed the ICMJE uniform disclosure form and declare: F.P.W. recognizes support from R01DK113191, R01HS027626 and P30DK079310, D.G.M. received support from National Institutes of Health awards K23DK117065 and R01DK128087, and C.R.P. is supported by NIH grants R01HL085757; J.M.T. reports grants and/or personal fees from 3ive labs, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Astra Zeneca, Novartis, Cardionomic, MagentaMed, Reprieve inc., FIRE1, W.L. Gore, Sanofi, Sequana Medical, Otsuka, Abbott, Merck, Windtree Therapeutics, Lexicon pharmaceuticals, Precardia, Relypsa, Regeneron, BD, Edwards life sciences, and Lilly; D.G.M. and C.R.P. are co-inventors of the pending patent application “Methods and Systems for Diagnosis of Acute Interstitial Nephritis”. C.R.P. is a member of the advisory board of and owns equity in RenalytixAI. He also serves as a consultant for Genfit and Novartis. In addition, J.M.T. has a patent Treatment of diuretic resistance issued to Yale and Corvidia Therapeutics Inc, a patent Methods for measuring renalase issued to Yale, and a patent Treatment of diuretic resistance pending with Reprieve inc.